Bookmark

Add to MyYahoo RSS

Alexion Pharmaceuticals News

News on Alexion Pharmaceuticals (Ticker: ALXN) continually updated from thousands of sources around the net.

Yesterday | Seeking Alpha

Alexion Looks Better After Q2 Earnings

Alexion reported earnings last week that failed to excite investors as the share price went down in the next two days.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Fri Jul 25, 2014

AmericanBankingNews.com

Stifel Nicolaus Reiterates Buy Rating for Alexion Pharmaceuticals

's stock had its "buy" rating reiterated by investment analysts at Stifel Nicolaus in a note issued to investors on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

The Hartford Courant

Alexion Profits Up 38% From A Year Earlier

Alexion Pharmaceuticals, the highly successful biotech company headquartered in Cheshire, grew profits by more than $70 million in the second quarter of 2014 compared with the same period a year earlier, as more patients start on Soliris, which is then needed for the rest of their lives.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Cheshire, CT, New Haven, CT

Thu Jul 24, 2014

Forbes.com

Thursday Sector Laggards: Materials, Healthcare

The worst performing sector as of midday Thursday is the Materials sector, not showing much of a gain.

Comment?

Related Topix: Industrial Machines, Precision Castparts, Aerospace-Defense, Metals, Real Estate, Freeport, Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Investor's Business Daily

Celgene, Alexion Beat Estimates, But Biotechs Fall

Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector.

Comment?

Related Topix: Biotech, Celgene, Medicine, Healthcare Industry, Taligen Therapeutics

Seeking Alpha

Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript

Good morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2014 Results Conference Call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

BioSpace

Alexion Pharmaceuticals Inc. Release: European Medicines Agency...

Alexion Pharmaceuticals, Inc. today announced that the Marketing Authorization Application for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia , has been validated and granted accelerated assessment by the European Medicines Agency .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Marketing

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

The International Center for Dispute R... )--Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECU... Resumen: La Agencia Europea del Medicamento acepta la solicitud de autorizacin de marketing de Asfotasa Alfa como tratamiento ... (more)

Comment?

Related Topix: TapImmune, Marketing, Biotech, Healthcare Industry

Freshnews

Alexion Reports Second Quarter 2014 Results

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law

Fri Jul 18, 2014

Investor's Business Daily

Will New Drug Give Alexion Pharmaceuticals A Boost?

In October, the FDA awarded breakthrough therapy designation for ALXN1101, a new drug Alexion is developing to treat hypophosphatasia, or HPP, an ultrarare metabolic disorder.

Comment?

Related Topix: Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Forbes.com

Friday Sector Leaders: Utilities, Healthcare

The best performing sector as of midday Friday is the Utilities sector, up 1.1%.

Comment?

Related Topix: Pacific Star Communications, Pinnacle West Capital Corporation, Energy, Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Taligen Therapeutics

Wed Jul 16, 2014

Sys-Con Media

Pegasystems Appoints Anne Warner General Counsel and Chief Compliance Officer

Ms. Warner will be responsible for leading Pegasystems' global legal and compliance groups.

Comment?

Related Topix: Pegasystems, Software, Chordiant Software, Startups, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Cheshire, CT

Customer Interaction Solutions

Alexion Announces the Appointments of David R. Brennan, M. Michele...

Alexion Pharmaceuticals, Inc. today announced the appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to the Company's Board of Directors, effective immediately.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, AstraZeneca, AstraZeneca Group, Merck , Insurance, Marsh and Mclennan Companies

Thu Jul 10, 2014

AmericanBankingNews.com

Zacks Downgrades Alexion Pharmaceuticals to Neutral

They currently have a $173.00 target price on the stock. Zacks 's price target would suggest a potential upside of 6.21% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

The Motley Fool

3 Stocks Near 52-Week Highs Worth Selling

With the S&P 500 and Dow Jones Industrial Average making new records on a nearly weekly basis, it should come as no surprise that new 52-week highs outnumber new lows by a lot .

Comment?

Related Topix: Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

Customer Interaction Solutions

Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014

Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter ended June 30, 2014 on Thursday, July 24, 2014 before the US financial markets open.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Taligen Therapeutics

Thu Jul 03, 2014

Benzinga

Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday.

Comment?

Related Topix: Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Amgen, Enbrel, Etanercept (generic)

Tue Jul 01, 2014

Forbes.com

Tuesday Sector Leaders: Healthcare, Technology & Communications

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, up 1.5%.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Taligen Therapeutics, Computers, Seagate Technology

Californiaexaminer.net

Unusual Option Trades: Amicus Therapeutics

It appears biopharm stocks are hot, and getting hotter. Two of today's most unusual, large option trades involve Amicus Therapeutics , and Alexion Pharmaceuticals .

Comment?

Related Topix: Amicus, Startups, Financial Markets, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••